Please login to the form below

Not currently logged in
Email:
Password:

respiratory syncytial virus

This page shows the latest respiratory syncytial virus news and features for those working in and with pharma, biotech and healthcare.

Moderna launches phase 1/2 study of mRNA-based flu vaccine

Moderna launches phase 1/2 study of mRNA-based flu vaccine

The company is also planning to explore potential combination vaccines that protect against flu, SARS-CoV-2 (COVID-19), respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). ... Respiratory combination vaccines are an important pillar of

Latest news

More from news
Approximately 2 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • Well-funded life sciences firms are making long-term progress – and their investors are too Well-funded life sciences firms are making long-term progress – and their investors are too

    Up to that point, the drug was being developed to treat respiratory viral infections in patients with COPD who are at risk of experiencing exacerbations, which can be deadly and typically ... challenge study, in this case respiratory syncytial virus (RSV)

  • COVID-19: the race to find a vaccine COVID-19: the race to find a vaccine

    In the absence of a knockout antiviral, researchers are trying to mitigate harmful effects of the virus. ... Scientists have since industrialised the concept, leading to the development of antibodies against Ebola and respiratory syncytial virus.

  • Getting multichannel marketing right Getting multichannel marketing right

    has encouraged people to knit hats and blankets for babies to alert people to respiratory syncytial virus.

  • Deal Watch March 2017 Deal Watch March 2017

    In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD) ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Alios has an oral anti-viral in phase 2 for treatment of infant respiratory syncytial virus (RSV) which complements J&J's early stage programmes in RSV.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...